Descrizione

A study by StrategyHelix indicates that the global clinical next-generation sequencing market is expected to increase by US$ 18.4 miliardi da 2022 A 2028, ottenendo un CAGR di 23.4% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for clinical next-generation sequencing. The global clinical next-generation sequencing market is segmented on the basis of component, disease class, disease category, test complexity, test purpose, e regione. Based on component, the global clinical next-generation sequencing market is categorized into instrument, workflow solution (kits, servizi, ecc.). On the basis of disease class, the global clinical next-generation sequencing market has been segmented into cancer, non-cancer. The non-cancer segment captured the largest share of the market in 2021. By disease category, the global clinical next-generation sequencing market has been segmented into cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation. Secondo la ricerca, the oncology segment had the largest share in the global clinical next-generation sequencing market. Based upon test complexity, the global clinical next-generation sequencing market is categorized into hotspot, multi-gene, single gene, whole genome, whole/targeted exome. The multi-gene segment held the largest revenue share in 2021. On the basis of test purpose, the global clinical next-generation sequencing market has been segmented into diagnosis, monitoring, screening/early detection, therapy guidance. In termini di geografia, the global clinical next-generation sequencing market has been segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The global clinical next-generation sequencing market is highly competitive. As of 2021, the major players in the global clinical next-generation sequencing market were ANGLE plc, Becton Dickinson and Company, BGI Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Techne Corporation, Burning Rock Biotech Limited, CareDx Inc., Danaher Corp., Epigenomics AG, Eurofins Scientific SE, EXACT Sciences Corporation, Fulgent Genetics Inc., GeneDx Inc., Guardant Health Inc., Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Qiagen N.V., Quest Diagnostics Incorporated, Roche Holding AG, Thermo Fisher Scientific Inc.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the clinical next-generation sequencing market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Component: instrument, workflow solution (kits, servizi, ecc.)
Disease class: cancer, non-cancer
Disease category: cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation
Test complexity: hotspot, multi-gene, single gene, whole genome, whole/targeted exome
Test purpose: diagnosis, monitoring, screening/early detection, therapy guidance
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global clinical next-generation sequencing market
– Identificare le strategie regionali e le priorità strategiche sulla base dei dati locali
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Clinical next-generation sequencing market overview
Parte 3. Market breakdown by component
– Instrument
– Workflow solution (kits, servizi, ecc.)
Parte 4. Market breakdown by disease class
– Cancer
– Non-cancer
Parte 5. Market breakdown by disease category
– Cardiovascular
– Clinical microbiology and infectious diseases
– Mendelian disorders
– Metabolic/immune
– Neurological
– Oncology
– Reproductive health
– Transplantation
Parte 6. Market breakdown by test complexity
– Hotspot
– Multi-gene
– Single gene
– Whole genome
– Whole/targeted exome
Parte 7. Market breakdown by test purpose
– Diagnosis
– Monitoring
– Screening/early detection
– Therapy guidance
Parte 8. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 9. Aziende chiave
– ANGLE plc
– Becton, Dickinson and Company
– BGI Group
– Biocept, Inc.
– Biodesix, Inc.
– Biolidics Limited
– Bio-Techne Corporation
– Burning Rock Biotech Limited
– CareDx, Inc.
– Danaher Corp.
– Epigenomics AG
– Eurofins Scientific SE
– EXACT Sciences Corporation
– Fulgent Genetics Inc.
– GeneDx Inc.
– Guardant Health, Inc.
– Illumina, Inc.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, Inc.
– NeoGenomics Laboratories, Inc.
– Qiagen N.V.
– Quest Diagnostics Incorporated
– Roche Holding AG
– Thermo Fisher Scientific Inc.
Informazioni su StrategyHelix
Disclaimer